|Mr. Ian C. Read||Chairman and Chief Exec. Officer||6.38M||11.48M||63|
|Mr. Frank A. D'Amelio||Chief Financial Officer and Exec. VP of Bus. Operations||3.24M||6.11M||60|
|Dr. Mikael Dolsten M.D., Ph.D.||Pres of Worldwide R&D and Exec. VP||4.2M||3.33M||58|
|Mr. John D. Young||Group Pres of Pfizer Essential Health||4.42M||1.15M||52|
|Mr. Albert Bourla DVM, Ph.D.||Group Pres of Pfizer Innovative Health||4.07M||587.28k||55|
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc.’s ISS Governance QualityScore as of June 2, 2017 is 1. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 2; Compensation: 1.